Fulgent Genetics (FLGT) Capital Expenditures (2015 - 2026)

Fulgent Genetics has disclosed Capital Expenditures across 12 years of filings, most recently posting $3.9 million for Q2 2026.

• In Q2 2026, Capital Expenditures fell 43.48% year-over-year to $3.9 million; the TTM figure through Jun 2026 stood at $20.1 million (down 42.37% YoY), while the FY2025 annual figure was $22.6 million, down 44.01% from the prior year.
• Capital Expenditures came in at $3.9 million for Q2 2026 at Fulgent Genetics, down from $5.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $19.5 million in Q3 2024 to a low of $2.0 million in Q1 2023.
• Average Capital Expenditures over 5 years is $6.3 million, with a median of $5.0 million recorded in 2023.
• Year-over-year, Capital Expenditures jumped 296.85% in 2024 and sank 69.03% in 2025.
• Over 5 years, Capital Expenditures stood at $4.7 million in 2022, then slumped by 34.22% to $3.1 million in 2023, then gained by 21.64% to $3.8 million in 2024, then jumped by 31.82% to $5.0 million in 2025, then slipped by 22.53% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $3.9 million in Q2 2026, $5.2 million in Q1 2026, and $5.0 million in Q4 2025.